Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: M. Ramle who wrote (842)	5/6/1998 1:09:00 AM
From: John Metcalf	Read Replies (1) of 10280

Granted, ENMD bounced way too high for a company with only pre-clinical murine results. However, at maximum apogee, Entremed only reached a little over $1 billion in market cap. SEPR has been at the $1.4B mark for some time on primary share value; add a couple hundred million more fully diluted. The long-term rise in the stock and relative stability of the price suggests that institutions (and individuals) are buying and holding it. Sepracor is a very unusual candidate for trading -:) In regard to selling covered calls, I can't see how sixty cents premium is a valid reward for the risk that news, a Lilly deal for example, or Levalbuterol approval, or another patent, could come at any time.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next